menu
    • menu
    [{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minzasolmin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"UCB Pharma S.A \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Minzasolmin","moa":"Alpha synuclein misfolding","graph1":"Neurology","graph2":"Phase II","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neuropore Therapies \/ UCB Pharma S.A","highestDevelopmentStatusID":"8","companyTruncated":"Neuropore Therapies \/ UCB Pharma S.A"}]

    Find Clinical Drug Pipeline Developments & Deals for Minzasolmin

    Menu

    Minzasolmin

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UCB Pharma S.A

                            Belgium arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minzasolmin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minzasolmin Proof-of-Concept Study Shapes UCB Parkinson’s Research Program Next Steps

                            Details :

                            Product Name : UCB0599

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 16, 2024

                            Lead Product(s) : Minzasolmin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minzasolmin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : UCB Pharma S.A

                            Deal Size : $460.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement wit...

                            Details : UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration entered into between Neuropore Therapies and UCB Biopharma on December, 2014. This milestone payment is a result of the continued clinical ...

                            Product Name : UCB0599

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : Minzasolmin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : UCB Pharma S.A

                            Deal Size : $460.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth